Table 4 Univariate analysis in patients with/without bleeding events
Non-bleeding group ( n = 198) | Bleeding group ( n = 19) | p value | |
|---|---|---|---|
Age, median(IQR) | 56 (47–62) | 63 (53–65) | 0.007 |
Male gender (%) | 87 (43.9%) | 5 (26.3%) | 0.138 |
BMI,median(IQR) | 23.1 (21.5–26.9) | 21.2 (18.7–24.0) | 0.032 |
With other site VTE | |||
Pulmonary thromboembolism | 6 (3.0%) | 2 (10.5%) | 0.148 |
Lower extremity Deep vein thrombosis | 14 (7.1%) | 3 (15.8%) | 0.176 |
VTE history | 12 (6.1%) | 1 (5.3%) | 1.000 |
Bleeding history | 7 (3.5%) | 4 (21.1%) | 0.009 |
Primary cancer | 0.711 | ||
Breast | 52 (26.3%) | 7 (36.8%) | |
Lymphoma | 38 (19.2%) | 2 (10.5%) | |
Gastrointestinal | 57 (28.8%) | 4 (21.1%) | |
Gynecology | 22 (11.1%) | 3 (15.8%) | |
Lung | 29 (14.6%) | 3 (15.8%) | |
With metastasis (%) | 78 (39.4%) | 12 (63.2%) | 0.045 |
ECOG performance | 0.627 | ||
0 | 56 (28.3%) | 4 (21.1%) | |
1 | 82 (41.4%) | 10 (52.6%) | |
2 | 60 (30.3%) | 5 (26.3%) | |
Antiangiogenic therapy used | 51 (25.8%) | 2 (10.5%) | 0.171 |
Underlying diseases/conditions | |||
Cardiovascular disease | 37 (18.7%) | 4 (21.1%) | 0.763 |
Diabetes | 19 (9.6%) | 3 (15.8%) | 0.419 |
Abnormal Renal function (30 ml/min ≤ CrCl < 60 ml/min) | 9 (4.5%) | 3 (15.8%) | 0.076 |
Reduced platelet (Platelet count < 100 × 10^9/L) | 10 (5.1%) | 3 (15.8%) | 0.093 |
Anemia(Hemoglobin < 130 g/L for man, < 120 g/L for woman) | 29 (14.6%) | 6 (31.6%) | 0.055 |
Non-single lumen PICC | 8 (4.0%) | 0 | 1.000 |
Left arm insertion | 31 (15.7%) | 3 (15.8%) | 1.000 |
Exit site infection | 7 (3.5%) | 2 (10.5%) | 0.181 |
Treatment pattern (LMWH) | 112 (56.6%) | 6 (31.6%) | 0.037 |
Anticoagulation duration (days), median (IQR) | 180 (125–180) | 163 (128–1) | 0.725 |
Outcome | |||
Recurrent VTE | 3 (1.5%) | 1 (5.3%) | 0.309 |
Death from any cause | 3 (1.5%) | 0 | 1.000 |